Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury

Kidney International

Volumn 78, Issue 12, 2010, Pages 1252-1262

  Metzger, Jochen ^a   Kirsch, Torsten ^b   Schiffer, Eric ^a   Ulger, Perihan ^c   Mentes, Ebru ^c   Brand, Korbinian ^b   Weissinger, Eva M ^b   Haubitz, Marion ^b   Mischak, Harald ^a,d   Herget Rosenthal, Stefan ^c,e  

^a MOSAIQUES DIAGNOSTICS GMBH   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e Rotes Kreuz Krankenhaus   (Germany)

Author keywords

acute kidney injury; acute renal failure; diagnosis; proteomics

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; COLLAGEN TYPE 1; CYSTATIN C; FIBRINOGEN; INTERLEUKIN 18; KIDNEY INJURY MOLECULE 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; POLYPEPTIDE;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMINO TERMINAL SEQUENCE; ARTICLE; CAPILLARY ELECTROPHORESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE MARKER; EARLY DIAGNOSIS; FEMALE; HUMAN; INTENSIVE CARE UNIT; KIDNEY FUNCTION; KIDNEY INJURY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; SEQUENCE ANALYSIS; URINALYSIS; URINARY EXCRETION; VALIDATION PROCESS;

EID: 78649641356     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.322     Document Type: Article

References (71)

1. Chertow GM, Burdick E, Honour M et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005; 16: 3365-3370.
2. Hoste EA, Clermont G, Kersten A et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 2006; 10: R73.
3. Lassnigg A, Schmid ER, Hiesmayr M et al. Impact of minimal increases in serum creatinine on outcome in patients after cardiothoracic surgery: do we have to revise current definitions of acute renal failure? Crit Care Med 2008; 36: 1129-1137.
4. Yohannes S, Chawla LS. Evolving practices in the management of acute kidney injury in the ICU (intensive care unit). Clin Nephrol 2009; 71: 602-607.
5. Ricci Z, Ronco C. Today's approach to the critically ill patient with acute kidney injury. Blood Purif 2009; 27: 127-134.
6. Mehta RL, Kellum JA, Shah SV et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31.
7. Bellomo R. Defining, quantifying, and classifying acute renal failure. Crit Care Clin 2005; 21: 223-237.
8. Devarajan P. Cellular and molecular derangements in acute tubular necrosis. Curr Opin Pediatr 2005; 17: 193-199.
9. Star RA. Treatment of acute renal failure. Kidney Int 1998; 54: 1817-1831.
10. Herget-Rosenthal S, Marggraf G, Husing J et al. Early detection of acute renal failure by serum cystatin C. Kidney Int 2004; 66: 1115-1122.
11. Parikh CR, Abraham E, Ancukiewicz M et al. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol 2005; 16: 3046-3052.
12. Mishra J, Dent C, Tarabishi R et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005; 365: 1231-1238.
13. Han WK, Waikar SS, Johnson A et al. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int 2008; 73: 863-869.
14. Koyner JL, Bennett MR, Worcester EM et al. Urinary cystatin C as an early biomarker of acute kidney injury following adult cardiothoracic surgery. Kidney Int 2008; 74: 1059-1069.
15. Wagener G, Gubitosa G, Wang S et al. Urinary neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery. Am J Kidney Dis 2008; 52: 425-433.
16. Haase M, Bellomo R, Story D et al. Urinary interleukin-18 does not predict acute kidney injury after adult cardiac surgery: a prospective observational cohort study. Crit Care 2008; 12: R96.
17. Han WK, Wagener G, Zhu Y et al. Urinary biomarkers in the early detection of acute kidney injury after cardiac surgery. Clin J Am Soc Nephrol 2009; 4: 873-882.
18. Coca SG, Parikh CR. Urinary biomarkers for acute kidney injury: perspectives on translation. Clin J Am Soc Nephrol 2008; 3: 481-490.
19. Hampel DJ, Sansome C, Sha M et al. Toward proteomics in uroscopy: urinary protein profiles after radiocontrast medium administration. J Am Soc Nephrol 2001; 12: 1026-1035.
20. Schaub S, Wilkins JA, Antonovici M et al. Proteomic-based identification of cleaved urinary beta2-microglobulin as a potential marker for acute tubular injury in renal allografts. Am J Transplant 2005; 5: 729-738.
21. Vanhoutte KJ, Laarakkers C, Marchiori E et al. Biomarker discovery with SELDI-TOF MS in human urine associated with early renal injury: evaluation with computational analytical tools. Nephrol Dial Transplant 2007; 22: 2932-2943.
22. Nguyen MT, Ross GF, Dent CL et al. Early prediction of acute renal injury using urinary proteomics. Am J Nephrol 2005; 25: 318-326.
23. Bennett MR, Ravipati N, Ross G et al. Using proteomics to identify preprocedural risk factors for contrast induced nephropathy. Proteomics Clin Appl 2008; 2: 1058-1064.
24. Theodorescu D, Wittke S, Ross MM et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 2006; 7: 230-240.
25. Dakna M, He Z, Yu WC et al. Technical, bioinformatical and statistical aspects of liquid chromatography-mass spectrometry (LC-MS) and capillary electrophoresis-mass spectrometry (CE-MS) based clinical proteomics: a critical assessment. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 1250-1258.
26. Ho J, Lucy M, Krokhin O et al. Mass spectrometry-based proteomic analysis of urine in acute kidney injury following cardiopulmonary bypass: a nested case-control study. Am J Kidney Dis 2009; 53: 584-595.
27. Herget-Rosenthal S, Poppen D, Husing J et al. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin Chem 2004; 50: 552-558.
28. Verroust PJ, Birn H, Nielsen R et al. The tandem endocytic receptors megalin and cubilin are important proteins in renal pathology. Kidney Int 2002; 62: 745-756.
29. Lebeau C, Debelle FD, Arlt VM et al. Early proximal tubule injury in experimental aristolochic acid nephropathy: functional and histological studies. Nephrol Dial Transplant 2005; 20: 2321-2332.
30. Bonventre JV. Mechanisms of ischemic acute renal failure. Kidney Int 1993; 43: 1160-1178.
31. Birn H, Christensen EI. Renal albumin absorption in physiology and pathology. Kidney Int 2006; 69: 440-449.
32. Candiano G, Musante L, Bruschi M et al. Repetitive fragmentation products of albumin and alpha1-antitrypsin in glomerular diseases associated with nephrotic syndrome. J Am Soc Nephrol 2006; 17: 3139-3148.
33. Daemen MA, Heemskerk VH, van't VC et al. Functional protection by acute phase proteins alpha(1)-acid glycoprotein and alpha(1)-antitrypsin against ischemia/reperfusion injury by preventing apoptosis and inflammation. Circulation 2000; 102: 1420-1426.
34. Nechemia-Arbely Y, Barkan D, Pizov G et al. IL-6/IL-6R axis plays a critical role in acute kidney injury. J Am Soc Nephrol 2008; 19: 1106-1115.
35. Simmons EM, Himmelfarb J, Sezer MT et al. Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int 2004; 65: 1357-1365. (Pubitemid 38406974)
36. Chawla LS, Seneff MG, Nelson DR et al. Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis. Clin J Am Soc Nephrol 2007; 2: 22-30.
37. Strutz F, Zeisberg M, Ziyadeh FN et al. Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int 2002; 61: 1714-1728.
38. Arosalo BM, Raekallio M, Rajamaki M et al. Detecting early kidney damage in horses with colic by measuring matrix metalloproteinase-9 and-2, other enzymes, urinary glucose and total proteins. Acta Vet Scand 2007; 49: 4.
39. Van PM, Van OR, Velders GA et al. Serpina1 is a potent inhibitor of IL-8-induced hematopoietic stem cell mobilization. Proc Natl Acad Sci USA 2006; 103: 1469-1474.
40. Okada Y, Watanabe S, Nakanishi I et al. Inactivation of tissue inhibitor of metalloproteinases by neutrophil elastase and other serine proteinases. FEBS Lett 1988; 229: 157-160.
41. Gomez DE, Alonso DF, Yoshiji H et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997; 74: 111-122.
42. Forbes JM, Hewitson TD, Becker GJ et al. Ischemic acute renal failure: long-term histology of cell and matrix changes in the rat. Kidney Int 2000; 57: 2375-2385.
43. Basile DP, Donohoe D, Roethe K et al. Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. Am J Physiol Renal Physiol 2001; 281: F887-F899.
44. Persy VP, Verhulst A, Ysebaert DK et al. Reduced postischemic macrophage infiltration and interstitial fibrosis in osteopontin knockout mice. Kidney Int 2003; 63: 543-553.
45. Basile DP, Fredrich K, Weihrauch D et al. Angiostatin and matrix metalloprotease expression following ischemic acute renal failure. Am J Physiol Renal Physiol 2004; 286: F893-F902.
46. Schmitt R, Coca S, Kanbay M et al. Recovery of kidney function after acute kidney injury in the elderly: a systematic review and meta-analysis. Am J Kidney Dis 2008; 52: 262-271. (Pubitemid 351978133)
47. Watanabe R, Wada H, Sakakura M et al. Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states. Am J Hematol 2000; 65: 35-40.
48. Gupta A, Berg DT, Gerlitz B et al. Role of protein C in renal dysfunction after polymicrobial sepsis. J Am Soc Nephrol 2007; 18: 860-867.
49. Sutton TA, Mang HE, Campos SB et al. Injury of the renal microvascular endothelium alters barrier function after ischemia. Am J Physiol Renal Physiol 2003; 285: F191-F198.
50. Enestrom S, Druid H, Rammer L. Fibrin deposition in the kidney in post-ischaemic renal damage. Br J Exp Pathol 1988; 69: 387-394.
51. Nangaku M, Alpers CE, Pippin J et al. A new model of renal microvascular endothelial injury. Kidney Int 1997; 52: 182-194.
52. Sires UI, Murphy G, Baragi VM et al. Matrilysin is much more efficient than other matrix metalloproteinases in the proteolytic inactivation of alpha 1-antitrypsin. Biochem Biophys Res Commun 1994; 204: 613-620.
53. Li W, Savinov AY, Rozanov DV et al. Matrix metalloproteinase-26 is associated with estrogen-dependent malignancies and targets alpha1-antitrypsin serpin. Cancer Res 2004; 64: 8657-8665.
54. Nelson D, Potempa J, Travis J. Inactivation of alpha1-proteinase inhibitor as a broad screen for detecting proteolytic activities in unknown samples. Anal Biochem 1998; 260: 230-236.
55. Zhang Z, Winyard PG, Chidwick K et al. Proteolysis of human native and oxidised alpha 1-proteinase inhibitor by matrilysin and stromelysin. Biochim Biophys Acta 1994; 1199: 224-228.
56. Rossing K, Mischak H, Dakna M et al. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008; 19: 1283-1290.
57. Coon JJ, Zürbig P, Dakna M et al. CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl 2008; 2: 964-973.
58. Julian BA, Wittke S, Novak J et al. Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases. Electrophoresis 2007; 28: 4469-4483.
59. Lo LJ, Go AS, Chertow GM et al. Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int 2009; 76: 893-899.
60. Liangos O, Tighiouart H, Perianayagam MC et al. Comparative analysis of urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass. Biomarkers 2009; 14: 423-431.
61. Nejat M, Pickering JW, Walker RJ et al. Rapid detection of acute kidney injury by plasma cystatin C in the intensive care unit. Nephrol Dial Transplant 2010.
62. Knepper MA. Common sense approaches to urinary biomarker study design. J Am Soc Nephrol 2009; 20: 1175-1178.
63. Levey AS, Coresh J, Greene T et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254.
64. Taylor CF, Paton NW, Lilley KS et al. The minimum information about a proteomics experiment (MIAPE). Nat Biotechnol 2007; 25: 887-893.
65. Mischak H, Apweiler R, Banks RE et al. Clinical proteomics: a need to define the field and to begin to set adequate standards. Proteomics Clin Appl 2007; 1: 148-156.
66. Kolch W, Neususs C, Pelzing M et al. Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom Rev 2005; 24: 959-977.
67. Theodorescu D, Fliser D, Wittke S et al. Pilot study of capillary electro-phoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis 2005; 26: 2797-2808.
68. Wittke S, Fliser D, Haubitz M et al. Determination of peptides and proteins in human urine with capillary electrophoresis-mass spectrometry, a suitable tool for the establishment of new diagnostic markers. J Chromatogr A 2003; 1013: 173-181.
69. Jantos-Siwy J, Schiffer E, Brand K et al. Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res 2009; 8: 268-281.
70. Good DM, Wirtala M, McAlister GC et al. Performance characteristics of electron transfer dissociation mass spectrometry. Mol Cell Proteomics 2007; 6: 1942-1951.
71. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc B (Methodological) 1995; 57: 125-133.